Evidence map›Paper›PMID 34566709›Full record

ArticleFrontiers in psychiatry2021

Hybrid Cognitive Behavioral Therapy With Interoceptive Exposure for Irritable Bowel Syndrome: A Feasibility Study.

Misako Funaba, Hitomi Kawanishi, Yasushi Fujii, Koyo Higami, Yoshitoshi Tomita, Kazushi Maruo, Norio Sugawara, Yuki Oe, Satsuki Kura, Masaru Horikoshi and 6 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Interoceptive Processing in Functional Gastrointestinal Disorders.International journal of molecular sciences · 2024
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 1 country.

Misako FunabaDepartment of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Hitomi KawanishiDepartment of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Yasushi FujiiDepartment of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Koyo HigamiShinjuku-Gyoenmae Counseling Center, Tokyo, Japan.
Yoshitoshi TomitaDepartment of Psychosomatic Medicine, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Japan.
Kazushi MaruoDepartment of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Norio SugawaraDepartment of Psychiatry, Dokkyo Medical University School of Medicine, Mibu, Japan.
Yuki OeDepartment of Neuropsychiatry, Kyorin University School of Medicine, Mitaka, Japan.
Satsuki KuraHidaka Dental Clinic, Fukuoka, Japan.
Masaru HorikoshiNational Center for Cognitive Behavioral Therapy and Research, National Center of Neurology and Psychiatry, Kodaira, Japan.
Chisato OharaDepartment of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Hiroe KikuchiDepartment of Psychosomatic Medicine, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan.
Hajime ArigaDivision of Gastroenterology, Department of General Internal Medicine, National Center Hospital, National Center of Neurology and Psychiatry, Kodaira, Japan.
Shin FukudoDepartment of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
Atsushi SekiguchiDepartment of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
Tetsuya AndoDepartment of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Japan.
National Center of Neurology and Psychiatry · JPNational Institute of Mental Health · JPBunkyo University · JPDokkyo Medical University · JPHidaka Hospital · JPMeisei University · JPNational Center for Global Health and Medicine · JPTohoku University · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder, which severely impairs the quality of life of patients. Treatment of refractory IBS patients is needed, but it is not yet widely available. Therefore, we previously developed a Japanese version of cognitive behavioral therapy with interoceptive exposure (CBT-IE) involving 10 face-to-face sessions to treat refractory IBS patients. To disseminate this treatment of IBS in places where therapists are limited, we further developed a hybrid CBT-IE program with complementary video materials that include psychoeducation and homework instructions so that patients can prepare for face-to-face sessions in advance at home and the session time can be shortened, thereby reducing the burden on both patient and therapist. In this study, we conducted a trial to evaluate the feasibility, efficacy, and safety of the hybrid CBT-IE program for Japanese IBS patients. The study was a single-arm, open-label pilot clinical trial. A total of 16 IBS patients were included in the study and 14 patients completed the intervention, which consisted of 10 weekly individual hybrid CBT-IE sessions. We performed an intention to treat analysis. The primary outcome measure for the efficacy of the intervention was a decrease in the severity of IBS symptoms. The feasibility and safety of the intervention were examined by the dropout rate and recording of adverse events, respectively. The dropout rate of the hybrid CBT-IE was comparable to that of our previous CBT-IE with only face-to-face sessions and no adverse events were recorded. The severity of IBS symptoms within-group was significantly decreased from the baseline to mid-treatment [Hedges' g = -0.98 (-1.54, -0.41)], post-treatment [Hedges' g = -1.48 (-2.09, -0.88)], 3-month follow-up [Hedges' g = -1.78 (-2.41, -1.14)], and 6-month follow-up [Hedges' g = -1.76 (-2.39, -1.13)]. Our results suggest that the hybrid CBT-IE is effective and could be conducted safely. To confirm the effectiveness of the hybrid CBT-IE, it is necessary to conduct a multicenter, parallel-design randomized control trial.

Indexed as

cognitive behavioral therapy with interoceptive exposurecomplementary video materialsfeasibility studyhybrid CBTirritable bowel syndrome

Identifiers

PMID34566709
PMCPMC8458884
OpenAlexW3200251144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.